Non-invasive Biomarkers for Metastatic Prostate Cancer

Share this content:
Can liquid biopsy and molecular imaging biomarkers help inform more precise management of patients with metastatic prostate cancer?
Can liquid biopsy and molecular imaging biomarkers help inform more precise management of patients with metastatic prostate cancer?

Editor's note: This article was updated to reflect changes requested by a source.

Because prostate cancer has a long natural history, decision-making about systemic therapy that could be informed by treatment response–predicting biomarkers can come several years after initial diagnosis, noted Himisha Beltran, MD, a medical oncologist and researcher specializing in genitourinary cancers at Weill Cornell Medicine and its Institute for Precision Medicine in New York, New York.

“A lot of the biomarker work has been to try to figure out which patients will respond to these drugs or additional, newer drugs designed to target the androgen receptor,” Dr Beltran told Cancer Therapy Advisor.

Given that male sex hormones fuel prostate tumor growth, androgen receptor (AR) mutations and amplifications are frequently involved in acquired tumor resistance to initial androgen-targeting treatment. Yet there is emerging evidence — preclinical thus far — that RB1 and p53 mutations drive androgen resistance, Dr Beltran noted.1

Detecting tumors' acquisition of these mutations in liquid biopsies of circulating tumor DNA could allow more timely shifts to other treatment options. Liquid biopsies could also open up management of metastatic prostate cancer to more precise treatment decision-making.

RELATED: Custirsen Fails in Phase 3 Prostate Cancer Trial

Working with the Stand Up to Cancer-Prostate Cancer Foundation Dream Team, Dr Beltran has helped examine tumor biopsy DNA and RNA from 150 men with metastatic castration-resistant prostate cancer (mCRPC) to identify candidate molecular biomarkers for identifying treatment outcomes. The team plans to sequence tumors and follow 500 patients with prostate cancer over the coming few years. These tools could help with more accurate patient risk stratification, matching patients to the best treatments, and inform patients and family members about potential inherited genetic risk factors.2,3

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs